Compugen Ltd.
https://www.cgen.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Compugen Ltd.
Gilead’s Trispecific Alliance With Merus Continues Its Push In Novel Cancer Tech
Deal Snapshot: Gilead adds to its pipeline of multispecific antibodies for cancer, while Merus gets a first partner for its trispecific platform.
Gilead Gets License To Compugen’s Potential First-In-Class IL-18 Target For Cancer
The company will pay $60m for rights to the preclinical asset COM503, which could be a new type of immuno-oncology drug.
Israeli Biopharma Leaders Focus On Near-Term Targets
Biopharma executives in Israel rely on their global footprint and a 'culture of resilience'.
BioBytes: Four Big Pharma Companies Cultivating AI-Based Start-ups
Through an Israeli innovation lab, four big pharma companies are fostering AI-driven start-ups to help solve industry problems.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
-
Large Molecule
- Other Names / Subsidiaries
-
- Evogene, Compugen USA, Inc, Neviah Genomics Ltd
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Compugen Ltd.
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice